SCHEMBL7208283

SCHEMBL7208283

COc1ccc2c(C(=O)N(C)OC)csc2c1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CLK1 P49759 5/20 0.52
DYRK1A Q13627 4/20 0.52
DYRK1B Q9Y463 1/20 0.52
ESR1 P03372 1/20 0.43
NPSR1 Q6W5P4 2/20 0.41
TSHR P16473 2/20 0.41
PRNP P04156 1/20 0.41
MAPK1 P28482 1/20 0.41
PPARG P37231 1/20 0.41
HTT P42858 1/20 0.41
MAPK10 P53779 1/20 0.41
NCOA2 Q15596 1/20 0.41
RXFP1 Q9HBX9 1/20 0.41
MAPT P10636 5/20 0.41
KDM4E B2RXH2 2/20 0.41
MEN1 O00255 1/20 0.41
CYP1A2 P05177 1/20 0.41
CYP2D6 P10635 1/20 0.41
HPGD P15428 1/20 0.41
CYP2C19 P33261 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2814704 0.81 CA12 (0.49) ESR1NPSR1TSHRPRNPMAPK1
SCHEMBL7206532 0.81 ALDH1A1 (0.51) DYRK1AESR1NPSR1TSHRPRNP
SCHEMBL2811677 0.80 KDM4E (0.49) DYRK1ADYRK1BESR1NPSR1TSHR
SCHEMBL19330261 0.80 HDAC3 (0.51) NPSR1HTTMAPTKDM4EMEN1
SCHEMBL2813714 0.76 NPSR1 (0.45) DYRK1AESR1NPSR1TSHRPRNP
SCHEMBL4654240 0.75 CES2 (0.56) CLK1DYRK1ADYRK1BNPSR1TSHR
SCHEMBL1324265 0.75 ALDH1A1 (0.50) NPSR1TSHRHTTMAPTKDM4E
SCHEMBL18940235 0.74 MAPK1 (0.67) CLK1DYRK1ADYRK1BNPSR1TSHR
SCHEMBL12857970 0.73 HTT (0.53) CLK1DYRK1ADYRK1BNPSR1TSHR
SCHEMBL4093630 0.73 CLK1 (0.52) CLK1DYRK1ADYRK1BMAPK1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1274706-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASES AGOURON PHARMACEUTICALS, INC. (US) 2003-01-15 EP disclosed
US-6462069-B2 KINASE INHIBITORS; ANTICANCER AGENTS AGOURON PHARMACEUTICALS, INC. 2002-10-08 US disclosed
WO-2001079198-A9 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMA (US) 2002-05-16 WO disclosed
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases LIGHPOINTE COMMUNICATION, INC. 2002-01-17 US disclosed
WO-2001079198-A1 PYRAZOLES FOR INHIBITING PROTEIN KINASE AGOURON PHARMACEUTICALS, INC. (US) 2001-10-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020006952-A1 Compounds, pharmaceutical compositions, and methods for inhibiting protein kinases CDK3, CCNK, CDK1 CLK1 377/4885DYRK1A 936/4885DYRK1B 851/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.